AU2022297795A1 - Regulatory nucleic acid sequences - Google Patents

Regulatory nucleic acid sequences Download PDF

Info

Publication number
AU2022297795A1
AU2022297795A1 AU2022297795A AU2022297795A AU2022297795A1 AU 2022297795 A1 AU2022297795 A1 AU 2022297795A1 AU 2022297795 A AU2022297795 A AU 2022297795A AU 2022297795 A AU2022297795 A AU 2022297795A AU 2022297795 A1 AU2022297795 A1 AU 2022297795A1
Authority
AU
Australia
Prior art keywords
nucleic acid
acid sequences
regulatory nucleic
regulatory
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022297795A
Other languages
English (en)
Inventor
Sinclair COOPER
Antonia EVRIPIOTI
Juan Manuel IGLESIAS
Michael L. Roberts
Jorge Omar YANEZ-CUNA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AskBio Inc
Original Assignee
AskBio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2108997.4A external-priority patent/GB202108997D0/en
Application filed by AskBio Inc filed Critical AskBio Inc
Publication of AU2022297795A1 publication Critical patent/AU2022297795A1/en
Assigned to ASKLEPIOS BIOPHARMACEUTICAL, INC. reassignment ASKLEPIOS BIOPHARMACEUTICAL, INC. Request for Assignment Assignors: ASKLEPIOS BIOPHARMACEUTICAL, INC., SYNPROMICS LIMITED
Assigned to AskBio Inc. reassignment AskBio Inc. Amend patent request/document other than specification (104) Assignors: ASKLEPIOS BIOPHARMACEUTICAL, INC.
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2022297795A 2021-06-23 2022-06-23 Regulatory nucleic acid sequences Pending AU2022297795A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2108997.4A GB202108997D0 (en) 2021-06-23 2021-06-23 Regulatory nucleic acid sequences
GB2108997.4 2021-06-23
GB2111317.0 2021-08-05
GB202111317 2021-08-05
PCT/GB2022/051611 WO2022269269A1 (en) 2021-06-23 2022-06-23 Regulatory nucleic acid sequences

Publications (1)

Publication Number Publication Date
AU2022297795A1 true AU2022297795A1 (en) 2024-01-04

Family

ID=82655313

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022297795A Pending AU2022297795A1 (en) 2021-06-23 2022-06-23 Regulatory nucleic acid sequences

Country Status (8)

Country Link
US (1) US20250129381A1 (https=)
EP (1) EP4359548A1 (https=)
JP (1) JP2024524270A (https=)
KR (1) KR20240023643A (https=)
AU (1) AU2022297795A1 (https=)
CA (1) CA3221707A1 (https=)
IL (1) IL309630A (https=)
WO (1) WO2022269269A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202319008D0 (en) * 2023-12-13 2024-01-24 Ucl Business Ltd AAV-mediated gene therapy of diseases caused by impaired function of GLDC

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US8106180B2 (en) 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
US20050142581A1 (en) 2003-09-04 2005-06-30 Griffey Richard H. Microrna as ligands and target molecules
WO2005056761A2 (en) 2003-12-05 2005-06-23 Massachusetts Institute Of Technology REAGENTS AND METHODS FOR IDENTIFICATION OF RNAi PATHWAY GENES AND CHEMICAL MODULATORS OF RNAi
KR100614827B1 (ko) 2004-05-06 2006-08-25 재단법인서울대학교산학협력재단 양방향 은닉 마코프 모델을 이용한 완숙한마이크로알엔에이 위치예측방법 및 이를 구현하기 위한컴퓨터 프로그램을 기록한 저장매체
PL3097197T3 (pl) * 2014-01-21 2021-06-28 Vrije Universiteit Brussel Mięśniowo-specyficzne elementy regulatorowe kwasów nukleinowych oraz sposoby i ich zastosowanie
TWI908746B (zh) * 2019-11-28 2025-12-21 美商銳進科斯生物股份有限公司 微小肌縮蛋白基因療法之構築體及其用途
EP4081643A1 (en) * 2019-12-24 2022-11-02 Asklepios Biopharmaceutical, Inc. Regulatory nucleic acid sequences
EP4192580A4 (en) * 2020-08-05 2025-06-18 AskBio Inc. Methods for treating heart disease and congestive heart failure and administration of AAV vectors
CA3195177A1 (en) * 2020-10-07 2022-04-14 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i)

Also Published As

Publication number Publication date
JP2024524270A (ja) 2024-07-05
WO2022269269A1 (en) 2022-12-29
EP4359548A1 (en) 2024-05-01
KR20240023643A (ko) 2024-02-22
IL309630A (en) 2024-02-01
CA3221707A1 (en) 2022-12-29
US20250129381A1 (en) 2025-04-24

Similar Documents

Publication Publication Date Title
GB2598497B (en) Nucleic acid hybridization methods
EP4107288A4 (en) NUCLEIC ACID PROBES
EP3963105A4 (en) METHOD FOR DETECTING NUCLEIC ACID VARIANTS
GB201913898D0 (en) Nucleic acid construct
GB201818816D0 (en) Regulatory nucleic acid sequences
IL318225A (en) Nucleic acid compounds
IL318227A (en) Nucleic acid compounds
IL318229A (en) Nucleic acid compounds
GB202005179D0 (en) Methods for the selection of nucleic acid sequences
AU2022297795A1 (en) Regulatory nucleic acid sequences
EP4178971A4 (en) RNA scaffolds
GB202013940D0 (en) Regulatory nucleic acid sequences
GB202005732D0 (en) Regulatory nucleic acid sequences
HK40111006A (en) Regulatory nucleic acid sequences
HK40095336A (zh) 调节核酸序列
HK40089076A (en) Regulatory nucleic acid sequences
CA3276549A1 (en) Regulatory nucleic acid sequences
HK40082198A (en) Regulatory nucleic acid sequences
EP4200421A4 (en) NUCLEASE-MEDIATED NUCLEIC ACID MODIFICATION
EP4247827A4 (en) PURIFICATION OF RIBONUCLEIC ACID
GB202108997D0 (en) Regulatory nucleic acid sequences
GB202012192D0 (en) Regulatory nucleic acid sequences
EP4062976A4 (en) CARBALYSOPHOSPHATIDIC ACID
HK40059066A (en) Regulatory nucleic acid sequences
CA3289672A1 (en) Liver-specific regulatory nucleic acid sequences

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ASKLEPIOS BIOPHARMACEUTICAL, INC.

Free format text: FORMER APPLICANT(S): SYNPROMICS LIMITED; ASKLEPIOS BIOPHARMACEUTICAL, INC.

HB Alteration of name in register

Owner name: ASKBIO INC.

Free format text: FORMER NAME(S): ASKLEPIOS BIOPHARMACEUTICAL, INC.